Search

Displaying results 901 - 910 of 2482 in total
  1. Drug

    Alogliptin

    go.drugbank.com/drugs/DB06203
    ApprovedInvestigational

    Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes ...

    Mixtures: INCRESINA PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α1A subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  3. Drug

    Prasugrel

    go.drugbank.com/drugs/DB06209
    ApprovedInvestigational

    As a result, inhibition of ADP-mediated platelet activation and aggregation occurs.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  4. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  5. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher he...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  6. Drug

    Lacosamide

    go.drugbank.com/drugs/DB06218
    ApprovedInvestigational

    Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of intera...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    Nalmefene, a 6-methylene analogue of naltrexone, is an opioid receptor antagonist. It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. In Europe, nalmefene ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Ridaforolimus

    go.drugbank.com/drugs/DB06233
    Investigational

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  9. Drug

    Maribavir

    go.drugbank.com/drugs/DB06234
    ApprovedInvestigational

    Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation. Most standard CMV therapies, such as ganciclovir or foscarnet, target CMV DNA polymerase - ...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both sildenafil and vardenafil but l...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates